Status:
RECRUITING
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
University Hospital, Marseille
Conditions:
Lupus Erythematosus, Systemic
Eligibility:
All Genders
18+ years
Brief Summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory re...
Detailed Description
Regarding the exploration of anti-C1s autoantibodies purified from the SLE patients' serum, the investigators will evaluate their effects on the formation of the C1r2C1s2 tetramer and interaction with...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Weight ≥ 40 Kg
- Patients who have valid health insurance
- Patients with lupus diagnosis criteria (EULAR-ACR-2019)
- Active lupus nephritis defined by SLEDAI score \>5 and joint and/or kidney involvement.
Exclusion
- Patient protected by law (minors, pregnant or breastfeeding women, subject under guardianship or curatorship, deprived of liberty or enforced hospitalized, under administrative or judicial supervision).
- Patient on dialysis or on plasma exchange.
Key Trial Info
Start Date :
March 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 10 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05193591
Start Date
March 11 2022
End Date
September 10 2025
Last Update
August 30 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble Alpes
Grenoble, France, 38043
2
AP-HM_Hôpital de la Conception
Marseille, France, 13005